Rituximab trough serum levels and Cmax concentrations with R-CHOP-14 (n = 20)
| Median rituximab dose, mg (range) | 671 (593-881) | ||
| Rituximab infusion rate, mg/h, n (range) | 224.4 (58.1-554.7) | ||
| Rituximab levels | |||
| Cycle 1 | μg/mL, median (range) | n (%) | |
| Before treatment | 0 | 20 (100) | |
| After treatment | 179.8 (133.9-254.8) | 18 (90) | |
| Cycle 2 | |||
| Before treatment | 38.9 (21.3-61.8) | 19 (95) | |
| After treatment | 219.3 (94.9-281.4) | 19 (95) | |
| Cycle 3 | |||
| Before treatment | 67.8 (47.0-108.8) | 19 (95) | |
| After treatment | 224.2 (159.4-349.6) | 18 (90) | |
| Cycle 4 | |||
| Before treatment | 93.0 (40.2-135.7) | 20 (100) | |
| After treatment | 251.9 (146.0-296.6) | 19 (95) | |
| Cycle 5 | |||
| Before treatment | 110.3 (54.9-156.7) | 20 (100) | |
| After treatment | 250.0 (191.6-359.8) | 20 (100) | |
| Cycle 6 | |||
| Before treatment | 118.0 (65.4-185.5) | 18 (90) | |
| After treatment | 275.1 (195.5-368.3) | 20 (100) | |
| Cycle 7 | |||
| Before treatment | 124.9 (24.5-206.8) | 19 (95) | |
| After treatment | 280.0 (185.5-398.7) | 20 (100) | |
| Cycle 8 | |||
| Before treatment | 115.9 (61.0-197.0) | 18 (90) | |
| After treatment | 273.2 (200.5-356.9) | 19 (95) | |
| 1 wk after therapy | 172.6 (91.4-286.1) | 14 (70) | |
| 1 mo after therapy | 91.4 (39.6-189.1) | 17 (85) | |
| 2 mo after therapy | 54.0 (16.1-122.9) | 16 (80) | |
| 3 mo after therapy | 30.1 (9.33-82.2) | 16 (80) | |
| 6 mo after therapy | 5.1 (0.8-14.7) | 15 (75) | |
| 9 mo after therapy | 1.1 (0-2.8) | 10 (50) | |
| Median rituximab dose, mg (range) | 671 (593-881) | ||
| Rituximab infusion rate, mg/h, n (range) | 224.4 (58.1-554.7) | ||
| Rituximab levels | |||
| Cycle 1 | μg/mL, median (range) | n (%) | |
| Before treatment | 0 | 20 (100) | |
| After treatment | 179.8 (133.9-254.8) | 18 (90) | |
| Cycle 2 | |||
| Before treatment | 38.9 (21.3-61.8) | 19 (95) | |
| After treatment | 219.3 (94.9-281.4) | 19 (95) | |
| Cycle 3 | |||
| Before treatment | 67.8 (47.0-108.8) | 19 (95) | |
| After treatment | 224.2 (159.4-349.6) | 18 (90) | |
| Cycle 4 | |||
| Before treatment | 93.0 (40.2-135.7) | 20 (100) | |
| After treatment | 251.9 (146.0-296.6) | 19 (95) | |
| Cycle 5 | |||
| Before treatment | 110.3 (54.9-156.7) | 20 (100) | |
| After treatment | 250.0 (191.6-359.8) | 20 (100) | |
| Cycle 6 | |||
| Before treatment | 118.0 (65.4-185.5) | 18 (90) | |
| After treatment | 275.1 (195.5-368.3) | 20 (100) | |
| Cycle 7 | |||
| Before treatment | 124.9 (24.5-206.8) | 19 (95) | |
| After treatment | 280.0 (185.5-398.7) | 20 (100) | |
| Cycle 8 | |||
| Before treatment | 115.9 (61.0-197.0) | 18 (90) | |
| After treatment | 273.2 (200.5-356.9) | 19 (95) | |
| 1 wk after therapy | 172.6 (91.4-286.1) | 14 (70) | |
| 1 mo after therapy | 91.4 (39.6-189.1) | 17 (85) | |
| 2 mo after therapy | 54.0 (16.1-122.9) | 16 (80) | |
| 3 mo after therapy | 30.1 (9.33-82.2) | 16 (80) | |
| 6 mo after therapy | 5.1 (0.8-14.7) | 15 (75) | |
| 9 mo after therapy | 1.1 (0-2.8) | 10 (50) | |